跳至主要内容
临床试验/CTRI/2024/01/061731
CTRI/2024/01/061731尚未招募4 期

The examination of the upper therapeutic threshold of serum clozapine level in treatment-resistant Schizophrenia: A double-blind randomized controlled trial.

Indian Council of Medical Research, New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Diagnosis of Schizophrenia as per ICD 11
  • Diagnosed with treatment resistant schizophrenia for positive symptoms subdomain as per the Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines
  • Male gender
  • 18-45 years of age
  • No active use of tobacco after about 7 days of clozapine initiation

排除标准

  • 1. Uncooperative for psychopathology assessment
  • 2. Need for Electroconvulsive therapy
  • 3. A recent history of high-grade fever or infection within the past two weeks
  • 4. Co-existing disease that can potentially influence nervous system
  • 5. Treatment with medications known to affect nervous systems or serum clozapine levels
  • 6. Co-morbid substance abuse or dependence except for nicotine dependence syndrome; co-morbid Axis I Psychiatry disorder
  • 7. Any significant medical or neurological disorder that might interfere with sleep or cognition.

研究者

发起方
Indian Council of Medical Research, New Delhi

相似试验